Twist Bioscience Expands High-Throughput IgG Antibody Portfolio with Launch of CHO Express Antibodies

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of its high-throughput antibody portfolio with the launch of a CHO cell line for Twist Express Antibodies. Twist also offers HEK293 expression Twist Express Antibodies. “With the majority of biotherapeutic drugs manufactured in CHO cell lines, expressing smal
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks